1119 related articles for article (PubMed ID: 26296750)
1. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.
Ito MK
Atherosclerosis; 2015 Oct; 242(2):647-56. PubMed ID: 26296750
[TBL] [Abstract][Full Text] [Related]
2. TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
Handelsman Y; Shapiro MD
Endocr Pract; 2017 Jan; 23(1):100-112. PubMed ID: 27819772
[TBL] [Abstract][Full Text] [Related]
3. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
4. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.
Marston NA; Giugliano RP; Im K; Silverman MG; O'Donoghue ML; Wiviott SD; Ference BA; Sabatine MS
Circulation; 2019 Oct; 140(16):1308-1317. PubMed ID: 31530008
[TBL] [Abstract][Full Text] [Related]
5. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
Jacobson TA
Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
[TBL] [Abstract][Full Text] [Related]
6. Triglycerides: a case for treatment?
Wierzbicki AS; Clarke RE; Viljoen A; Mikhailidis DP
Curr Opin Cardiol; 2012 Jul; 27(4):398-404. PubMed ID: 22565137
[TBL] [Abstract][Full Text] [Related]
7. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
8. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
[TBL] [Abstract][Full Text] [Related]
9. Approach to Hypertriglyceridemia in the Pediatric Population.
Valaiyapathi B; Sunil B; Ashraf AP
Pediatr Rev; 2017 Sep; 38(9):424-434. PubMed ID: 28864733
[TBL] [Abstract][Full Text] [Related]
10. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
Breuer HW
Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
[TBL] [Abstract][Full Text] [Related]
11. Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients?
Drexel H
Fundam Clin Pharmacol; 2009 Dec; 23(6):687-92. PubMed ID: 19682084
[TBL] [Abstract][Full Text] [Related]
12. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.
Chapman MJ; Ginsberg HN; Amarenco P; Andreotti F; Borén J; Catapano AL; Descamps OS; Fisher E; Kovanen PT; Kuivenhoven JA; Lesnik P; Masana L; Nordestgaard BG; Ray KK; Reiner Z; Taskinen MR; Tokgözoglu L; Tybjærg-Hansen A; Watts GF;
Eur Heart J; 2011 Jun; 32(11):1345-61. PubMed ID: 21531743
[TBL] [Abstract][Full Text] [Related]
13. Triglycerides and endothelial function: molecular biology to clinical perspective.
Kajikawa M; Higashi Y
Curr Opin Lipidol; 2019 Oct; 30(5):364-369. PubMed ID: 31348023
[TBL] [Abstract][Full Text] [Related]
14. Cumulative non-HDL-cholesterol burden in patients with hypertriglyceridemia receiving long-term fibrate therapy: Real life data from a lipid clinic cohort.
Kayıkçıoğlu M; Shahbazova S; İbrahimov F; Can LH
Turk Kardiyol Dern Ars; 2020 Jun; 48(4):359-367. PubMed ID: 32519982
[TBL] [Abstract][Full Text] [Related]
15. Nonstatin therapies for management of dyslipidemia: a review.
Sando KR; Knight M
Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
[TBL] [Abstract][Full Text] [Related]
16. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements.
Miller M; Tokgozoglu L; Parhofer KG; Handelsman Y; Leiter LA; Landmesser U; Brinton EA; Catapano AL
Expert Rev Cardiovasc Ther; 2022 Aug; 20(8):609-625. PubMed ID: 35876118
[TBL] [Abstract][Full Text] [Related]
17. Fibrates and niacin: is there a place for them in clinical practice?
Wierzbicki AS; Viljoen A
Expert Opin Pharmacother; 2014 Dec; 15(18):2673-80. PubMed ID: 25318657
[TBL] [Abstract][Full Text] [Related]
18. Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention.
Quispe R; Sweeney T; Varma B; Agarwala A; Michos ED
Curr Atheroscler Rep; 2022 Oct; 24(10):767-778. PubMed ID: 35895246
[TBL] [Abstract][Full Text] [Related]
19. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.
McKenney JM; Sica D
Pharmacotherapy; 2007 May; 27(5):715-28. PubMed ID: 17461707
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with statins and omega-3 fatty acids.
Nambi V; Ballantyne CM
Am J Cardiol; 2006 Aug; 98(4A):34i-38i. PubMed ID: 16919515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]